Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed by Revio and commercialized by Welding through the partnership across the United States, Europe, and select global markets. A New Standard in Patient-Centric Oncology Care This collaboration combines Revio’s innovative 505(b)(2) drug development expertise with Welding’s commercial market access capabilities as well as therapeutic area expertise, positioning both organizations to address critical unmet needs in oncology patient care. Consistent with Revio’s business model of de-risking early, the program achieved a key milestone…